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Commentary on Ho et al. (2019): Managing people with
HIV and drug problems is complex and multi-faceted
International literature reviews can provide important
insights into global drug use and HIV infection treatment.
Management of HIV-infected individuals with coexisting
drug problems requires a range of services, including medical
prescribing, but crucially these must be engaged,
sympathetic and supportive of those people who are
estranged and marginalized.
This paper by Ho et al. [1] is important, because it gives us
an insight into the complexity of managing people who in-
ject drugs and the impact and influence of life-style, pov-
erty, adversity and the current limitations of public health
policy in many, if not most, countries. The importance of
life-style and economic stresses and the consequent need
to accommodate difficulties in these areas should not need
to be highlighted, but they are clearly an essential, and fre-
quently missed, part of public health policy and clinical
practice when delivering critical treatment to people
constrained by drug use difficulties.
The paper also draws attention to how people who use
drugs are perceived and supported. In doing so, it strikes at
the heart of many challenges for service delivery [1]. These
cluster around drug policy, stigma inhibiting change, vari-
ations between administrations, multi-drug use complicat-
ing risks, comorbid mental health problems and the
dynamics between identifying the evidence supporting
treatment and translating this into actions in affected
communities.
An additional message that we might extrapolate is the
importance of people who inject drugs (PWID) for the
impact of the world-wide HIV/AIDS epidemic, which is
now driven by drug injecting in many countries (especially
in Asia and increasingly in Africa) [2]. Adherence to
anti-retroviral therapy is constrained, not surprisingly, by
ongoing drug use and various other factors that alert us
to the focused attention needed to provide quality treat-
ment services delivered with compassion and sufficient
resources.
The lessons of the last 30 years are that administrations
experiencing drug use epidemics and managing and
preventing HIValways seem to struggle to implement effec-
tive interventions such as medically assisted treatment
(MAT) and needle and syringe availability. A binary ap-
proach between recovery/abstinence and harm reduction
is over-simplistic, and treatment services need to be much
more nuanced, personal and inclusive [3]. Despite an ex-
tensively researched and widely published literature draw-
ing attention to the benefits of engagement and retention
in MAT programmes [4,5], political decision-making and
consensus always seem to lag behind or, inmany cases, ob-
struct clinical practice.
Crises generate change, however [6], and there are
many examples of drug problems having dramatic effects
as unexpected problems require new approaches. The
United Kingdom changed drug policy in the 1980s in re-
sponse to HIV infection and, more recently, the United
States and Canada have had to make difficult political deci-
sions in the wake of an epidemic of fentanyl and oxycodone
use and overdose [7,8]. Indeed, the rising number of drug-
related deaths inmany countries is currently amajor driver
of drug policy change around the world, as it affects life ex-
pectancy and challenges conservative policy [9,10]. The
changes made need to destigmatize people who use drugs
and to reduce the barriers to treatment access by increas-
ing the targeted funding to support treatment services, en-
couraging research and inclusive practice.
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